Subscriber login:
Remember me
CLINICAL & FORMULARY MANAGEMENT STRATEGY
Review Formulary Management Considerations for Opportunities and Strategies and P&T Committee Planning Support
Access Published Guidelines, Health Outcomes, Pharmacoeconomics, and Clinical Trials
Anticipate Market Shifts, Pipeline Events, Manufacturer
Life-Cycle Management Strategies, and
Financial Implications
Understand Key Clinical, Cost, Utilization, Reimbursement, and Market-Competition Factors
IPD's Payer & Provider Insights combine advanced pharmaceutical landscape market visibility with a team of Executive Clinical Pharmacists to provide comprehensive pharmacy and therapeutic management strategy, supporting formulary, clinical, contracting, and market-access decisions.
Our subscribers gain around-the-clock access to IPD's proprietary web platform, real-time alerts, comprehensive reports, new drug reviews, podcast episodes, and expert consultations.
-
In-depth analysis regarding drug availability, clinical data, clinical pipeline tracking, evidence-based clinical pathways, preferred products, and site of care
-
Disease class-specific strategy reports, drug alerts, pipeline trend reports, and new-drug reviews
-
Assessments of potential new brand product prevalence and pricing impacts prior to launch
-
Extensive trend analysis examining brand vs. generic clinical pathways, cost-effective therapies, and payer perspectives
-
Pricing specific to competitive landscape including generic-launch projections, FDA action dates, sales, therapy costs, and price changes
-
Trend reports highlighting disease classes and drug events important to payers, systems, and manufacturers throughout the country
-
Clinical criteria, formulary coverage, step therapy, and limited distribution network tracking
Explore Recent Reports
December 2025
Rare Disease Management: Trends from 2024 Approvals
IPD Analytics has released a new report “Rare Disease Management: Trends from 2024 Approvals,” analyzing management trends for rare disease therapies approved in 2024, building on our earlier publication, “Rare Disease Drug Approvals—2024 Year in Review.” With more than 7,000 rare diseases affecting over 30 million people in the United States, rare conditions represent a growing area of clinical and payer focus.
December 2025
2026 Preview: 10 Trends to Anticipate
IPD Analytics has released a new report, “2026 Preview: 10 Trends to Anticipate,” outlining the key market, regulatory, and clinical developments that will shape payer strategy in the year ahead. As 2026 approaches, payers are preparing for rapid shifts driven by evolving drug approvals, ongoing regulatory changes, and continued pressure in high-spend therapeutic areas.